At present, the coexistence of several cardiovascular risk factors – obesity, diabetes mellitus, high cholesterol, sedentary lifestyle, smoking and high blood pressure, which are characteristic of today's society, have led to the emergence of a new cardiovascular pathology known as cardiac failure with the preserved systolic effect. This new form of inadequacy prevents proper heart release, as it affects almost half of patients with heart failure, both in Chile and in countries with higher levels of development.
So far, the mechanisms that they have created and the effective therapy for the treatment of this pathology have not been known. However, research conducted by scientists from the University of Chile and the Advanced Center for Chronic Diseases (ACCDiS), along with researchers at the Southwestern Medical Center of the University of Texas, found out how this disease occurs after replication in the animal model faithfully imitates what is happening in a human being, this is the discovery that opens the door for the development of healing.
The work carried out by Nature, the most important scientific journal on the planet, in an article titled "Nitroactive stress carries a heart failure with a preserved ejection fraction", describes that an increase in nitric oxide causes heart damage due to a change in the activity of the two proteins responsible for protecting the heart: IRE1α and XBP1s.
Chilean science for mankind
Heart failure is the final stage of multiple cardiovascular diseases, which are very common in our population, including hypertension and myocardial infarction. Experts believe that this pathology is an emerging epidemic, due to the increasing prevalence and high costs demanded by health systems that affect more than 26 million people worldwide and is the main cause of death in Chile (30% of deaths in country).
The team, composed of Gabriele Schiattarella, Joseph A. Hill and Francisco Altamirano, Elisa Villalobos and Sergio Lavandero, worked for more than seven years at the source of this new pathology and how to deal with it.
For Francisco Altamirano, this finding is "a gigantic achievement that will create future therapies for this new pathology."
Sergio Lavandero, director of ACCDiS, a professor at the Faculty of Chemical and Pharmaceutical Sciences and Medicine at the University of Chile and author of this study, emphasized that this new form of heart failure is a strategic issue for ACCDiS, because we must be in full harmony with current and future challenges heart and veins.
He also emphasized that the most important scientific journal in the world published this publication, including commenting on the supplementary note, because this discovery is of great importance. He also underlined the importance of cooperation between universities in the country and the support of the Concise Center of Excellence program in the priority areas of Fondap. Lavandero finally revealed the need to continue investing in science in order for the country to achieve a new level of development.
Gabriele Schiattarella stressed the fundamental role of Chilean scientists in this project. "Altamirano has contributed to deep biochemical knowledge, Villalobos has made fundamental experiments and Lavandero led me in the design and implementation of these research." To sum up, this publication in nature could not have happened without the contribution of this group of Chilean scientists. , he confirmed.